Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Treace Medical Concepts Inc (TMCI)

Treace Medical Concepts Inc (TMCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Treace to Report Third Quarter 2024 Financial Results on November 5, 2024

TMCI : 4.78 (+2.58%)
Treace Files Patent Infringement and Unfair Competition Suit to Protect Lapiplasty® Bunion Technology

SYK : 367.15 (+3.05%)
TMCI : 4.78 (+2.58%)
Treace Medical Concepts: Q2 Earnings Snapshot

Treace Medical Concepts: Q2 Earnings Snapshot

TMCI : 4.78 (+2.58%)
TREACE INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ("Treace"...

TMCI : 4.78 (+2.58%)
TREACE SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ("Treace"...

TMCI : 4.78 (+2.58%)
TREACE SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ("Treace"...

TMCI : 4.78 (+2.58%)
TREACE INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ("Treace"...

TMCI : 4.78 (+2.58%)
TREACE SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ("Treace"...

TMCI : 4.78 (+2.58%)
TREACE INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ("Treace"...

TMCI : 4.78 (+2.58%)
TREACE SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ("Treace"...

TMCI : 4.78 (+2.58%)

Barchart Exclusives

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy
Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a valuation a third cheaper than competitor, Eli Lilly. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar